Structure-guided AAV Capsid Evolution Strategies for Enhanced CNS Gene Delivery

Overview

Journal Nat Protoc

Specialties Biology
Pathology
Science

Date 2023 Sep 21

PMID 37735235

Authors

Trevor J Gonzalez

Aaron Mitchell-Dick

Leo O Blondel

Marco M Fanous

Joshua A Hull

Daniel K Oh

Sven Moller-Tank

Ruth M Castellanos Rivera

Jorge A Piedrahita

Aravind Asokan

Affiliations

Soon will be listed here.

Abstract

Over the past 5 years, our laboratory has systematically developed a structure-guided library approach to evolve new adeno-associated virus (AAV) capsids with altered tissue tropism, higher transduction efficiency and the ability to evade pre-existing humoral immunity. Here, we provide a detailed protocol describing two distinct evolution strategies using structurally divergent AAV serotypes as templates, exemplified by improving CNS gene transfer efficiency in vivo. We outline four major components of our strategy: (i) structure-guided design of AAV capsid libraries, (ii) AAV library production, (iii) library cycling in single versus multiple animal models, followed by (iv) evaluation of lead AAV vector candidates in vivo. The protocol spans ~95 d, excluding gene expression analysis in vivo, and can vary depending on user experience, resources and experimental design. A distinguishing attribute of the current protocol is the focus on providing biomedical researchers with 3D structural information to guide evolution of precise 'hotspots' on AAV capsids. Furthermore, the protocol outlines two distinct methods for AAV library evolution consisting of adenovirus-enabled infectious cycling in a single species and noninfectious cycling in a cross-species manner. Notably, our workflow can be seamlessly merged with other RNA transcript-based library strategies and tailored for tissue-specific capsid selection. Overall, the procedures outlined herein can be adapted to expand the AAV vector toolkit for genetic manipulation of animal models and development of human gene therapies.

Citing Articles

Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group.

Cavazza A, Molina-Estevez F, Plaza Reyes A, Ronco V, Naseem A, Malensek S Mol Ther Nucleic Acids. 2025; 36(1):102457.

PMID: 39991472 PMC: 11847086. DOI: 10.1016/j.omtn.2025.102457.

Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries.

Rosales A, Blondel L, Hull J, Gao Q, Aykun N, Peek J Nat Biomed Eng. 2025; .

PMID: 39910375 DOI: 10.1038/s41551-024-01341-0.

Oligodendrocytes, the Forgotten Target of Gene Therapy.

Ozgur-Gunes Y, Le Stunff C, Bougneres P Cells. 2024; 13(23).

PMID: 39682723 PMC: 11640421. DOI: 10.3390/cells13231973.

Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders.

Zhou L, Wang Y, Xu Y, Zhang Y, Zhu C Mol Ther Methods Clin Dev. 2024; 32(4):101357.

PMID: 39559557 PMC: 11570947. DOI: 10.1016/j.omtm.2024.101357.

Coarse-Grained Simulations of Adeno-Associated Virus and Its Receptor Reveal Influences on Membrane Lipid Organization and Curvature.

Pipatpadungsin N, Chao K, Rouse S J Phys Chem B. 2024; 128(41):10139-10153.

PMID: 39356546 PMC: 11492248. DOI: 10.1021/acs.jpcb.4c03087.

References

Mendell J, Al-Zaidy S, Rodino-Klapac L, Goodspeed K, Gray S, Kay C . Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2020; 29(2):464-488. PMC: 7854298. DOI: 10.1016/j.ymthe.2020.12.007. View

Kuzmin D, Shutova M, Johnston N, Smith O, Fedorin V, Kukushkin Y . The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021; 20(3):173-174. DOI: 10.1038/d41573-021-00017-7. View

Mingozzi F, High K . Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011; 12(5):341-55. DOI: 10.1038/nrg2988. View

Hudry E, Vandenberghe L . Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. Neuron. 2019; 101(5):839-862. PMC: 11804970. DOI: 10.1016/j.neuron.2019.02.017. View

Deverman B, Ravina B, Bankiewicz K, Paul S, Sah D . Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018; 17(9):641-659. DOI: 10.1038/nrd.2018.110. View

Rafii M, Tuszynski M, Thomas R, Barba D, Brewer J, Rissman R . Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2018; 75(7):834-841. PMC: 5885277. DOI: 10.1001/jamaneurol.2018.0233. View

Li C, Samulski R . Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020; 21(4):255-272. DOI: 10.1038/s41576-019-0205-4. View

Barnes C, Scheideler O, Schaffer D . Engineering the AAV capsid to evade immune responses. Curr Opin Biotechnol. 2019; 60:99-103. PMC: 7117822. DOI: 10.1016/j.copbio.2019.01.002. View

A Kotterman M, Schaffer D . Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014; 15(7):445-51. PMC: 4393649. DOI: 10.1038/nrg3742. View

10.

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

11.

Zolotukhin S, Vandenberghe L . AAV capsid design: A Goldilocks challenge. Trends Mol Med. 2022; 28(3):183-193. DOI: 10.1016/j.molmed.2022.01.003. View

12.

Gonzalez T, Simon K, Blondel L, Fanous M, Roger A, Maysonet M . Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat Commun. 2022; 13(1):5947. PMC: 9548504. DOI: 10.1038/s41467-022-33745-4. View

13.

Havlik L, Simon K, Smith J, Klinc K, Tse L, Oh D . Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. J Virol. 2020; 94(19). PMC: 7495376. DOI: 10.1128/JVI.00976-20. View

14.

Tse L, Klinc K, Madigan V, Castellanos Rivera R, Wells L, Havlik L . Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci U S A. 2017; 114(24):E4812-E4821. PMC: 5474820. DOI: 10.1073/pnas.1704766114. View

15.

Havlik L, Das A, Mietzsch M, Oh D, Ark J, McKenna R . Receptor Switching in Newly Evolved Adeno-associated Viruses. J Virol. 2021; 95(19):e0058721. PMC: 8428401. DOI: 10.1128/JVI.00587-21. View

16.

Albright B, Storey C, Murlidharan G, Castellanos Rivera R, Berry G, Madigan V . Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol Ther. 2017; 26(2):510-523. PMC: 5835146. DOI: 10.1016/j.ymthe.2017.10.017. View

17.

Murlidharan G, Corriher T, Ghashghaei H, Asokan A . Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. J Virol. 2015; 89(7):3976-87. PMC: 4403422. DOI: 10.1128/JVI.02951-14. View

18.

Shen S, Troupes A, Pulicherla N, Asokan A . Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J Virol. 2013; 87(24):13206-13. PMC: 3838263. DOI: 10.1128/JVI.02109-13. View

19.

Davidsson M, Wang G, Aldrin-Kirk P, Cardoso T, Nolbrant S, Hartnor M . A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism. Proc Natl Acad Sci U S A. 2019; 116(52):27053-27062. PMC: 6936499. DOI: 10.1073/pnas.1910061116. View

20.

Deverman B, Pravdo P, Simpson B, Kumar S, Chan K, Banerjee A . Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016; 34(2):204-9. PMC: 5088052. DOI: 10.1038/nbt.3440. View